STRATEGIC NEWS WATCH — June 23, 2026
What to Watch
- Sangamo bankruptcy auction: As court-supervised bidding proceeds, watch whether rivals top Lilly’s and Astellas’s stalking-horse offers and what becomes of unsold assets such as the hemophilia A gene therapy giroctocogene fitelparvovec — the outcome will reprice how distressed gene therapy portfolios are valued.
- Pfizer ADC pipeline review: After the Phase 3 lung cancer failure of a key Seagen-derived ADC, watch for any formal pipeline reassessment or investor guidance update, particularly on remaining ADC candidates and the return narrative for the $43 billion deal.
- Regenxbio BLA resubmission: With a July FDA meeting and a Q3 2026 resubmission on the calendar, signals on data requirements or label negotiations will indicate whether the gene therapy can reach market in 2027.
- Serapha Bio’s China exposure: The startup’s YolTech licensing deal warrants monitoring as US lawmakers continue scrutinizing China-linked biotech transactions; any CFIUS or legislative activity could reshape the deal structure.
- HHS clinical-trial strategy: The plan to restore US trial leadership is, for now, a policy document; watch for concrete mechanisms — FDA site-approval streamlining or NIH infrastructure funding — that would signal genuine execution.
This brief highlights the edition’s top stories. Read the latest edition → for all stories and analysis.
